Evidence map›Paper›PMID 31873775›Full record

ArticleEuropean archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery2020

SCORE risk scale as a prognostic factor after sudden sensorineural hearing loss.

Matteo Cavaliere, Pietro De Luca, Alfonso Scarpa, Massimo Ralli, Pompea Bottiglieri, Ettore Cassandro, Maurizio Iemma

Abstract readLetter
PubMed Publisher
In one paragraph

Article in European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 16 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Matteo CavaliereDepartment of Otolarhinolaryngology, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via Madonna di Fatima 53, 84084, Fisciano, Salerno, Italy. matorl@inwind.it.ORCID http://orcid.org/0000-0002-1742-1237
Pietro De LucaDepartment of Otolarhinolaryngology, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via Madonna di Fatima 53, 84084, Fisciano, Salerno, Italy.
Alfonso ScarpaDepartment of Otolarhinolaryngology, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via Madonna di Fatima 53, 84084, Fisciano, Salerno, Italy.
Massimo RalliDepartment of Sense Organs, Sapienza Unviersity of Rome, Rome, Italy.
Pompea BottiglieriDepartment of Intensive Cardiac Therapy, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Salerno, Italy.
Ettore CassandroDepartment of Otolarhinolaryngology, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via Madonna di Fatima 53, 84084, Fisciano, Salerno, Italy.
Maurizio IemmaDepartment of Otolarhinolaryngology, University Hospital "San Giovanni di Dio e Ruggi d'Aragona", Via Madonna di Fatima 53, 84084, Fisciano, Salerno, Italy.
Ospedali Riuniti San Giovanni di Dio e Ruggi d'Aragona · ITSapienza University of Rome · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Menezes et al. recently published an interesting study on cardiovascular prognostic factors for sudden sensorineural hearing loss (SSNHL), analyzing therapeutic strategies with intravenous and intratympanic corticosteroids and evaluating the application of the Systematic Coronary Risk Evaluation risk scale to classify risk in patients with SSNHL. In addition to intravenous and intratympanic corticosteroids, we would like to stress the role of hyperbaric oxygen therapy (HBOT). The new guidelines on SSNHL and the most recent scientific evidence emphasize the therapeutic role of HBOT. In a previous study, we recommended the use of HBOT in addition to intravenous steroid for patients with idiopathic SSNHL. For the best outcomes, we also recommended starting treatment within 14 days from the onset of SSNHL. In the same article, we discussed potential risk factors for SSNHL. Among cardiovascular risk factors, we suggest the possible association between patent foramen ovale (PFO) and SSNHL. The higher prevalence of PFO in our patients (50%) compared to controls suggests that SSNHL may be attributable to a paradoxical embolism, such as a venous embolism as a result of PFO.

Indexed as

Hearing Loss, SensorineuralHearing Loss, SuddenHyperbaric OxygenationAdrenal Cortex HormonesHumansPrognosisAdrenal Cortex HormonesHyperbaric oxygen therapyPatent foramen ovalRight-to-left shuntSudden sensorineural hearing loss

Identifiers

PMID31873775
OpenAlexW2995387457

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.